Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. (ALC) generates frequent news as a global eye care company listed on the SIX Swiss Exchange and the New York Stock Exchange. Company communications emphasize a long heritage in eye care, a broad Surgical and Vision Care portfolio, and a large international patient reach, which together make Alcon a regular subject of healthcare, medical device and capital markets coverage.
News about Alcon often highlights developments in its Surgical and Vision Care segments, including product launches and portfolio updates that address conditions such as cataracts, glaucoma, retinal diseases and refractive errors. The company has stated that it is advancing global launches of major products across these franchises, and such initiatives are typically announced through press releases and investor events.
Investors following ALC news can also expect updates on corporate strategy and transactions. For example, Alcon has reported on a definitive merger agreement with STAAR Surgical Company and later announced the termination of that agreement in a January 6, 2026 press release. These items appear in both company news and related regulatory filings, providing insight into how Alcon approaches acquisitions and refractive surgery strategy.
Coverage may further include Alcon’s participation in major healthcare conferences, where senior executives present the company’s outlook and discuss its Surgical and Vision Care businesses. Such events are typically accompanied by webcasts and formal announcements. By monitoring this news feed, readers can track key developments affecting Alcon’s product portfolio, strategic direction and presence in the global eye care market.
Summary not available.
Alcon (SIX/NYSE: ALC) will host its first in-person Annual General Meeting (AGM) since becoming independent in April 2019, on May 5, 2023. Key agenda items include approving annual financial statements for 2022 and the Board's proposal for a CHF 0.21 cash dividend per share, expected to be payable around May 12, 2023. The Board also proposes amendments to the Articles of Incorporation to align with recent Swiss corporate law reforms. Notably, no future virtual AGMs will be approved. Shareholders will vote on compensation for Board and Executive Committee members, among other items.
Alcon has received the Silver Anthem Award for its innovative compliance training program, The Lens, recognized as the Best Special Workforce Initiative: Health in the 2nd Annual Anthem Awards. Developed by Alcon’s Legal and Compliance team in collaboration with Labyrinth Training, The Lens features five interactive episodes addressing various compliance topics. Launched globally in 17 languages, it achieved an impressive completion rate of 81% among associates within 60 days. This recognition follows several other accolades received by Alcon, including awards for leadership and corporate social responsibility.
Alcon (NYSE: ALC), a leader in eye care, will host its 2023 Capital Markets Day on March 30, 2023, starting at 8:00 a.m. CT. The event will feature key updates and strategic insights, accessible via a live webcast at investor.alcon.com.
With over 75 years of history, Alcon offers a vast portfolio of surgical and vision care products, improving the lives of over 260 million people annually across 140 countries. Their commitment to enhancing quality of life through innovative eye care solutions is pivotal in addressing conditions like cataracts and glaucoma.
Alcon has launched TOTAL30 for Astigmatism, the first reusable Water Gradient toric lens, now available to U.S. Eye Care Professionals. This lens enhances comfort and mimics the ocular surface structure, addressing the needs of the growing astigmatic market. Alcon also showcases its expanded toric lens portfolio, including DAILIES TOTAL1 and PRECISION1 for Astigmatism, at the SECO International meeting in Atlanta. Clinical data presentations will highlight the efficacy of its vision care and dry eye products. Alcon's ongoing commitment to innovation aims to improve patient care and comfort in the ocular health sector.
Alcon reported fourth quarter 2022 sales of $2.2 billion, up 1% year-over-year, or 7% on a constant currency basis. For full-year 2022, sales reached $8.7 billion, a 5% increase, with diluted EPS at $0.68, down 11%, but up 37% in constant currency. Key segments included Surgical sales of $1.3 billion, a 1% increase, and Vision Care sales of $0.9 billion, up 1%. The company expects mid-to-high single-digit sales growth and high teens earnings growth for 2023, with a proposed dividend of CHF 0.21 per share subject to shareholder approval.
Alcon, a leader in eye care, has reached a settlement with J&J Surgical Vision, Inc. to resolve ongoing legal disputes over femtosecond laser assisted cataract surgery devices, particularly the LenSx® device. As part of this agreement, Alcon will pay USD 199 million to J&J for cross-licenses of certain intellectual property and to settle various worldwide intellectual property disputes. This settlement aims to mitigate legal uncertainties and enhance Alcon's operational focus, allowing it to continue its mission to improve global eye care.
Alcon (SIX/NYSE: ALC) has announced the launch of TOTAL30 for Astigmatism and DAILIES TOTAL1 for Astigmatism in Canada, expanding its range of innovative contact lenses for astigmatic patients. As the toric lens segment is rapidly growing, with only 10% of the 47% of patients needing correction currently using toric lenses, this launch addresses a significant market gap. The lenses utilize Alcon's proprietary Water Gradient technology, providing enhanced comfort and moisture retention. With added features like PRECISION BALANCE 8|4 lens design and CELLIGENT™ Technology, these products aim to improve wearers' experiences significantly.
Alcon (NYSE: ALC) has announced the launch of TOTAL30® for Astigmatism, the first reusable contact lens utilizing Water Gradient technology for astigmatic wearers. This innovative product enhances comfort and visual stability, targeting the $1.2 billion reusable toric lens market. Available in the U.S. and Europe from early 2023, TOTAL30 aims to improve the lens-wearing experience for astigmatic patients. The product features biomimetic CELLIGENT™ Technology to resist bacteria, ensuring a cleaner lens throughout the month.
Alcon (NYSE: ALC) CEO David Endicott will present at the 2023 J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 11:15 a.m. PST. A live webcast of the presentation will be available at investor.alcon.com/news-and-events/events-and-presentations. As a global leader in eye care, Alcon serves over 260 million people with products for conditions such as cataracts and glaucoma, emphasizing its commitment to enhancing sight and quality of life.